Clinical and Biochemical Phenotyping of Post-Viral Immunometabolic Disease
Institute for Neuro-Immune Medicine
447 views Feb 17, 2026
Clinical Research
In the first seminar of 2026 for the Institute for Neuro-Immune Medicine Research Seminar Series, Dr. Jonas Axelsson presents, “Clinical and Biochemical Phenotyping of Post-Viral Immunometabolic Disease,” with a focus on clinical strategies to better stratify patients with post-viral disease.
Dr. Axelsson discusses the physiological changes that occur in the body in the presence of autoimmune disease, examines immune-related risk factors that may predispose individuals to chronic dysfunction, and highlights how Ameliekliniken is advancing clinical understanding and evaluation of autoimmune conditions.Recognizing that medicine is both a science of uncertainty and an art of probability, Dr. Axelsson continues his efforts to refine diagnostic approaches and improve health outcomes for patients with autoimmunity and immunodeficiency.
Key points:
00:01 Introduction
02:56 Founding the Ameliekliniken in 2016
05:04 Post-viral fatigue as a defining symptom
06:50 Diagnosis without treatment is useless
08:21 Patients tell you the diagnosis
09:32 Treating different presentations as endotypes
10:41 Proving an autoimmune disease
12:59 Mitochondria beyond energy production
14:32 An immune hereditary risk
17:48 The risks of a suppressed mitochondria
18:47 EBV as a risk factor for many diseases
21:38 Possible EBV reactivation after COVID
23:19 Understanding diseases through Ameliekliniken
25:54 Defining mild immunodeficiency
27:33 Developing an EBV assay
29:13 Type 1 cold patients
31:33 Type 2 hot patients
34:54 How types 1 and 2 differ in energy production
41:08 Why we should focus on metabolites
43:15 Metabolic and treatment differences
44:51 Nutrition as the best response intervention
45:43 Significant improvement in SF36 physical component
48:44 The four principles of research success51:07 Safflower oil as an intervention53:37 E. coli’s effect on metabolism54:31 Akkermansia for type 1 cold patients55:54 Is vitamin D needed in treatments?57:27 Research lab for actual patients59:05 Long COVID patients with high EBNA01:00:000 Association os serratia to other infections01:02:04 Understanding EBV early antigen01:07:13 Early EBV clinical trialsDr. Jonas Axelsson is a physician specializing in Internal Medicine, Nephrology, Clinical Immunology, and Transfusion Medicine. From 2019 to 2024, he served as Medical Director of the Center for Aphresis and Stem Cell Therapy at Karolinska University Hospital in Stockholm, Sweden. From 2016 to 2022, he was an Associate Professor at Karolinska Institutet in Stockholm, Sweden.